Evidence map›Paper›PMID 41796974›Full record

ArticleAmerican journal of hematology2026

Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia.

Somedeb Ball, Farrukh T Awan, Ben K Tomlinson, Tess Stopczynski, Melissa A Fischer, Zhiguo Zhao, Kateryna Fedorov, Ashwin Kishtagari, Sanjay R Mohan, Gregory D Ayers and 2 more

2 registry-linked trialsAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03955783 phase1completednot on this map

An Investigator-Sponsored Phase Ib Trial of Venetoclax and SINE: Selective Inhibition of Nuclear Export in Patients with High Risk Hematologic Malignancies

TypeinterventionalSponsorSanjay MohanRan2019 to 2024Enrolled78ConditionsDiffuse Large B-cell Lymphoma, Acute Myeloid Leukemia, Non-Hodgkin's LymphomaArmsVenetoclax, Selinexor
NCT06399640 phase1recruitingnot on this map

Phase Ib Study of Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

TypeinterventionalSponsorVanderbilt-Ingram Cancer CenterRan2024 to 2027Enrolled60ConditionsRelapsed Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Recurrent Acute Myeloid LeukemiaArmsEltanexor, Venetoclax, Bone Marrow Aspiration and Biopsy, Biospecimen Collection
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Somedeb BallVanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Farrukh T AwanDivision of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0003-1813-9812
Ben K TomlinsonDepartment of Hematology and Stem Cell Transplant, University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA.
Tess StopczynskiDepartment of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Melissa A FischerDivision of Hematology and Oncology, Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Zhiguo ZhaoDepartment of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Kateryna FedorovVanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Ashwin KishtagariVanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Sanjay R MohanVanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Gregory D AyersDepartment of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Michael T ByrneVanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-2966-4877
Michael R SavonaVanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0003-3763-5504

Funding

Karyopharm Therapeutics
6 · The paper itself

Abstract

Preclinical studies showed a synergistic antileukemia activity with combination of selective XPO1 inhibitor selinexor (SEL) and venetoclax (VEN), with potential to overcome VEN resistance by reducing the anti-apoptotic protein MCL1. In an investigator-sponsored, open-label, phase Ib study (NCT03955783), adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) were enrolled. After the dose-escalation phase, SEL 80 mg po weekly plus VEN 400 mg/day following ramp-up was deemed the recommended phase II dose. Responses were assessed with IWG2003 and ELN 2022 criteria. Nineteen patients with R/R AML were enrolled. Median age at enrollment was 67.2 (range, 21.1-83.8) years. Overall, patients received median of 3 (range, 1-5) prior lines of therapy. The most common grade 3-5 treatment emergent adverse events (TEAE) were anemia (39%), neutropenia (33%), febrile neutropenia (28%), and thrombocytopenia (28%). Overall, the response rate with SEL-VEN was 21%. Two (11%) patients, one with prior allo-HSCT and one with prior VEN and both treated with SEL 80 mg/week, experienced complete remissions, with duration of response of 7 and 9.1 months, respectively. After a median follow up of 3.0 (range, 0.6-15.4) months, median event-free survival was 2.4 (95% CI: 1.9-12.1) months and median overall survival was 6.4 (95% CI: 2.5-12.1) months. In conclusion, SEL-VEN was feasible and active in a heavily pretreated AML cohort, with no new toxicity signal, but survival outcomes remained poor. The second-generation XPO1-inhibitor eltanexor, combined with VEN may further improve outcomes in VEN resistant AML in an ongoing study (NCT06399640).

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicHydrazinesLeukemia, Myeloid, AcuteSulfonamidesTriazolesAdultAgedAged, 80 and overDrug Resistance, NeoplasmFemaleHumansMaleMiddle AgedRecurrenceThrombocytopeniaBridged Bicyclo Compounds, HeterocyclicHydrazinesselinexorSulfonamidesTriazolesvenetoclax

Identifiers

PMID41796974
PMCPMC13055113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.